{"ticker": {"uuid": "bed0290f-10c3-46eb-9ae3-e4a990955009", "symbol": "GILD", "name": "Gilead Sciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZHpSRW9PU2dWLUFwMnk4ZGdvMjVMQjBRUWYyQk5kbFZxaS1MVko5WGlxZzFoeUhVdm5KeGhwQkRSbWhjV1ptQ1B1T084cFB3Q21vYWlPWTJZa1ptcGtNdmxwb0pHa0FHRTBWb1N4MUVQaEdpM01ROTBnTHEtMGFQT1E1VWpneGV0eHNEWFRucWRtaEYxRXZxT2d1YUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:11:31+00:00", "published_display": "15 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025. ", "url": "https://www.stocktitan.net/sec-filings/GILD/144-gilead-sciences-inc-sec-filing-54444559e606.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:38:11", "published_display": "15 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GILEAD SCIENCES For: 15 July By Investing.com", "summary": "This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-144-gilead-sciences-for-15-july-93CH-4736060", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:25:35", "published_display": "15 Jul 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBB ETF Holds Fewer Bets Than You Think", "summary": "The iShares Biotechnology ETF (IBB) appears diversified with 249 stocks, but its effective holdings are closer to 35 equally weighted positions due to significant concentration. The top ten holdings account for 44% of its assets, with Vertex Pharmaceuticals, Amgen, and Gilead Sci", "url": "https://www.trefis.com/stock/ibb/articles/607327/ibb-etf-holds-fewer-bets-than-you-think/2026-07-15", "source_name": "Trefis", "published_at": "2026-07-15T16:12:08", "published_display": "15 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?", "summary": "Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced \"death crosses\" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid", "url": "https://247wallst.com/investing/2026/07/15/is-the-bearishness-around-pfizer-and-gilead-sciences-a-contrarian-opportunity/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T13:10:37", "published_display": "15 Jul 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Gilead\u2019s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences (GILD) Investors?", "summary": "Gilead Sciences reported a Q3 revenue beat of US$6.96 billion, exceeding analysts' expectations by 1.5%, but concurrently issued a softer full-year earnings-per-share outlook. This outcome suggests that while sales are strong, the company faces challenges in translating this grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/should-gileads-revenue-beat-but-softer-eps-outlook-require-a", "source_name": "Simply Wall Street", "published_at": "2026-07-15T04:10:44", "published_display": "15 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day", "summary": "Shares of Gilead Sciences Inc. (GILD) closed down 1.04% at $130.04, despite an overall positive trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average seeing gains. The company's stock is currently trading 17.32% below its 52-week high of $1", "url": "https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-despite-losses-on-the-day-5e21e01f-dd5991da1067", "source_name": "MarketWatch", "published_at": "2026-07-14T16:35:00", "published_display": "14 Jul 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo", "summary": "Researchers in the Democratic Republic of Congo have initiated a trial for Gilead Sciences' experimental antiviral, obeldesivir, to be used as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak. The study, aimed at reducing the risk of Ebola infection after conta", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/congo-begins-trial-gileads-experimental-antiviral-ebola-bundibugyo-2026-07-14/", "source_name": "Reuters", "published_at": "2026-07-14T12:48:27", "published_display": "14 Jul 2026 12:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD)", "summary": "This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Medtronic (MDT), Quest Diagnostics (DGX), and Gilead Sciences (GILD). Analysts from Bank of America Securities maintained Buy ratings for all three, setting price targets that", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/3268979/analysts-offer-insights-on-healthcare-companies-medtronic-mdt-quest-diagnostics-dgx-and-gilead-sciences-gild/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T11:27:02", "published_display": "14 Jul 2026 11:27", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1", "summary": "This article analyzes the Q1 performance of Gilead Sciences and other key players in the therapeutics industry. While the sector generally performed well, with revenues beating estimates and share prices rising, individual companies showed varied results. Gilead Sciences reported", "url": "https://www.tradingview.com/news/stockstory:d119f2733094b:0-spotting-winners-gilead-sciences-nasdaq-gild-and-therapeutics-stocks-in-q1/", "source_name": "TradingView", "published_at": "2026-07-14T03:08:30", "published_display": "14 Jul 2026 03:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer", "summary": "Gilead Sciences, Inc. has announced that it has received all necessary regulatory approvals for its acquisition of Arcellx and has extended the tender offer for all outstanding shares of Arcellx common stock. The Australian Competition and Consumer Commission (ACCC) approved the ", "url": "https://www.natlawreview.com/press-releases/gilead-receives-all-required-regulatory-approvals-acquisition-arcellx-and", "source_name": "The National Law Review", "published_at": "2026-07-14T01:44:29", "published_display": "14 Jul 2026 01:44", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) AGM 2026 Summary", "summary": "The Gilead Sciences (GILD) AGM 2026 summary details the meeting's agenda, including the re-election of all nine director nominees. The board opposed shareholder proposals concerning an independent board chair, a report on patent exclusivity impact on patient access, and a report ", "url": "https://quartr.com/events/gilead-sciences-gild-agm-2026_3YENDubu", "source_name": "Quartr", "published_at": "2026-07-13T17:07:52", "published_display": "13 Jul 2026 17:07", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock outperforms competitors on strong trading day", "summary": "Gilead Sciences Inc. (GILD) saw its stock advance 1.21% to $131.40 on Monday, outperforming the broader market which experienced declines. The S&P 500 Index fell 0.79%, and the Dow Jones Industrial Average dropped 0.26% on the same trading day. This rise for Gilead Sciences Inc. ", "url": "https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-c04575bc-b4ac0b949a9e?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T16:35:00", "published_display": "13 Jul 2026 16:35", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLUE4TjFuWVFnYXp6R2NkZlhUblVRRkw5NTRpTGt0ZGhzZnBXQ09ZREFvTndDYTBEeDJveC1zMGk0R09Zb3EyNllpVm9vRmdtM2k2T3ByMy1uNFpTWENNT0p2TmxRcnlmd0E3bEFPbTM1eGN2Z1czNnY3UG0tdTF0ZUdhNXYxMnFkc0NwRVNyMlZENkNac0lvMHgtaGx1YkRjc2dEbmcxN21KNFZ3cHpHTGViOGVjMDIya1lmWkdPa29HaFI5VE5JazVQUi1GUTdESmJF?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:07+00:00", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.", "summary": "", "url": "https://finance.yahoo.com/m/c62745d4-bc96-3cd9-977e-fb163ba9e19e/many-investors-are-still.html", "source_name": "Motley Fool", "published_at": "2026-07-12T13:43:00+00:00", "published_display": "12 Jul 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Gilead Sciences, Inc. Stocks", "summary": "This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Gilead Sciences, Inc. (1GILD). The list details each ETF's market value, weight of Gilead stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, an", "url": "https://www.tradingview.com/symbols/MIL-1GILD/etfs/", "source_name": "TradingView", "published_at": "2026-07-11T10:37:49", "published_display": "11 Jul 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)", "summary": "Wells Fargo analyst Mohit Bansal has reiterated a Buy rating for Gilead Sciences (GILD) with a $165.00 price target. This comes after Gilead reported quarterly revenue of $6.96 billion and a net profit of $2.02 billion, exceeding the previous year's figures. JPMorgan also issued ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3236888/wells-fargo-sticks-to-their-buy-rating-for-gilead-sciences-gild/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T10:25:49", "published_display": "11 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 -- Data Talk", "summary": "Gilead Sciences is experiencing a significant stock decrease, down over 4% today. This puts the company on track for its largest single-day percentage decrease since July 2025, indicating a notable market reaction to recent events or news concerning the biopharmaceutical firm.", "url": "https://www.moomoo.com/news/post/72793765/gilead-sciences-down-over-4-on-pace-for-largest-percent", "source_name": "Moomoo", "published_at": "2026-07-11T06:07:58", "published_display": "11 Jul 2026 06:07", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts", "summary": "Gilead Sciences (GILD) stock declined 3.72% in its latest trading session while the broader market saw gains. Despite this daily dip, GILD's stock has outperformed both the Medical sector and the S&P 500 over the past month. Investors are awaiting Gilead's upcoming earnings repor", "url": "https://sg.finance.yahoo.com/news/gilead-sciences-gild-stock-dips-220003798.html", "source_name": "Market source", "published_at": "2026-07-10T21:37:41", "published_display": "10 Jul 2026 21:37", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Value $96.09 vs Price $129.83", "summary": "Gilead Sciences Inc (GILD) shares dropped 3.7% today, with its current price of $129.83 significantly exceeding its GF Value\u2122 of $96.09, indicating it is 35.1% overvalued. The stock's GF Score\u2122 of 69/100 suggests above-average performance, but recent insider selling of $10.8 mill", "url": "https://www.gurufocus.com/news/8954073/a-look-at-gilead-sciences-inc-gild-after-37-decline-gf-value-9609-vs-price-12983", "source_name": "GuruFocus", "published_at": "2026-07-10T21:22:40", "published_display": "10 Jul 2026 21:22", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors", "summary": "The article states that Gilead Sciences Inc. (GILD) stock underperformed on Friday compared to its competitors. No specific financial data for Gilead or its peers is provided in the very brief article.", "url": "https://www.msn.com/en-us/money/topstocks/gilead-sciences-inc-stock-underperforms-friday-when-compared-to-competitors/ar-AA27FnOL?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-10T20:42:44", "published_display": "10 Jul 2026 20:42", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)", "summary": "Morgan Stanley has resumed coverage of Lakefront Biotherapeutics (LKFT) with an \"Equal Weight\" rating and a $30 price target. This re-initiates coverage after Lakefront's acquisition of Ouro Medicines in June. The $1.7 billion deal was partly funded by Gilead.", "url": "https://seekingalpha.com/news/4612970-lakefront-draws-equal-weight-rating-morgan-stanley", "source_name": "Seeking Alpha", "published_at": "2026-07-10T17:08:13", "published_display": "10 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement", "summary": "Gilead Sciences Inc (GILD) stock fell by 3.26% on July 10, primarily due to the failure of a Phase 3 solid tumor clinical trial and broader macroeconomic pressures. Strong employment data contributed to increased Treasury yields, negatively impacting biotech valuations. Analysts ", "url": "https://www.tradingkey.com/news/market-movers/262023373-market-movers-gild-20260710", "source_name": "TradingKey", "published_at": "2026-07-10T16:14:48", "published_display": "10 Jul 2026 16:14", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNY1E2bG4zV2VnUU9lZVhURnJyd1ctbllUaGdvSHQyRnZFSXZXZWdDbUhSc2hPR3dkU0JqV09ONzhrTmVsVXc5WUZJV2RDSWs5aUVlUmp0U2kxdHlHSzJ2WHd1ZU8zSHFoQ3E4VHJQRWhCLXRySkZTU3RaTThHLXFidWtOaVRRNl8xeVlnaDJhWUx2RkJUOWdORjd4MTFkZU1ibHloOEZWeExuRjlGNDFSVnFSTlJINFBXZW1UVERIcDJoQk0xR1RrQ1NNOV9uZWZLR0lUOXVBUzIyWVZQWGpQZlRoSdIB6AFBVV95cUxOUjRkNlB2c0JZUVBOOS1nY3hHZnQyU1ItdVh5WWJaQjJla2xSbEdmTDVpbHk3bnBncUUyVjZ1SE42SFE5NmVWdDAyb0NzdldscHRVR2RBTXhWc2E1Ry0xNU12dWZhUnhuTDZTcXdWbGxRVXEtZnF0SFVpN0Z4WUt5anpiMlkyN0lLN0xMazEtRzhZLXlPamFxTWFoTjZBTm9uSkl5NU9yUVRYQmhwb2tnZXJucmpXUDR3UWpteXc0RjRFaFpPa1FkTF8wakF1OEZiRUZxLTFjMmpBREdDcXFmbGwyRDhlNlRs?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T15:28:27+00:00", "published_display": "09 Jul 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-sciences-gild-cheap-trodelvy-151037212.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T15:10:37+00:00", "published_display": "09 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-wins-trodelvy-071211614.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T07:12:11+00:00", "published_display": "09 Jul 2026 07:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-sciences-gild-russell-growth-061146402.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T06:11:46+00:00", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Keeps Buy Rating on Gilead (GILD)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/morgan-stanley-keeps-buy-rating-204826865.html", "source_name": "Insider Monkey", "published_at": "2026-07-08T20:48:26+00:00", "published_display": "08 Jul 2026 20:48", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Could Be 53% Below Fair Value After Trodelvy Approval", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T12:13:04+00:00", "published_display": "08 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Trodelvy\u2019s First-Line TNBC Approval Redefine Gilead Sciences\u2019 (GILD) Oncology-Led Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQb1Y3U09pU3plcjhBLVR4YnlEWmpXY3dFRHI4NXlnck5mMjN2WTQ3X2IxYVlULUVSVGM2T1lFY2xIb0VqaE9rZ1NkWTBKS3FMTFpReDM5MlBZcEZfQ3lrNUxGNl9nRnBDV2cybE5LTUFJNUdIdklTRVRvbWNobkpkbU1ibDFXVkhGdjEtU2ZhdGJoUFBibldISDBB?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could This FDA Milestone Unlock Gilead\u2019s (GILD) Next Big Growth Driver?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQT29NS01sMmtTVjF4MDhFYXpGUU9yMTFVSjFIMXRkRGYxMEZXR294X2ZfU2lNbEhPQ1Qyd1hxM0JjUm00UDFfOVJEQk8xVWp3QldqRXVLb0RIZVFPdjNFUnhwS2hwbGhfVGliS0JoQzM0b3c5ZjFwQXRXNkcyS1VxRVpYMktLX2plTGdzbWtkVTUxemtfZHlCcTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPQk1DTTdDeWFIb0JSZWdIamtYVzlxcnJ5THpBM2lfR0VLQ1lqamRMVS16eThoOUcyZjA3UmpNTkVlVzdsYVJtV04tUy05S1NVQkZ5Q2hMa1NzUDQxUThNcU5Qc1hGSTV3NUs4eEg5azhEX0xyaWJGQm93UmFnejg2bk5UdUM3bGs2bWV6YTZ4WkJRX1RlTFR5QUI1TWNBZFpUZlMxekZYMHY4UmV2YlNHSHM1aTBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNajlJV3A3cnJBMngzSGVaWlRZUmFzRWZhMmdBZlYxd3RFMUlfdTlEenNMbHVPMmVMWlg5MVd4Vlk2MFFjbGRkTC11Y0ZYVWlVV3ZYLXFMZ21nRmt0cnVfNDFkbEpqVzJoLUI2aWpIMkdRUkRheGR1V1FMV2N5Qk5XSF9xZExjUzFxd3RuX3NDWGt1Tk1fdkRzMU5wRnlNdVhqVWtRamE3QWEtY0JpUEpjU2ZSbFJTSkdJd1ZoRUF1VkI2ZmIxUzB2dHhXRjFNTnAwcFBYQl9IRG9yeHdtZEVsSQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ3RhTlFnWC1qTkw3YXFtQ0pBSmEtYW8zRGdPUzhJNVhQQjhBUmtlRkszQzJNaGM3MXlYb0tmV0tWWHNscG8yV1pIaXV0NnJLRVhpaF9Ub3NWYWxLOUdhQ2JrSnlkSnBHenloWGsxRUtDaHhReHNkZWVEVTA5di01ZmI3QVRVX09SREwzQkJfSUJVNGNEM1lrUVRsR3hrdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQR3hpb21Xd2lQalJiYnBZWlQ1QmhabDZrUlhQRjRfMnlfeUFnTEE3ZW9QZ3IyYkdtUGhiZTREOGc1RFI2UjRjeU1DcnZnTWhtR3JrOWhKNXlqQm9oWG8yZjltZ3hNdDFqTFJXWGRrYmp4bTZjSjlTV3g3Sk1yVk1vQ0ZsSkQyZlRXcEpjeUtzSXNyQXdUQXlGeFd1bS1oWUxqcjBmS2JxRXBIcDJw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's drug wins first-ever US approval for deadly liver infection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOY1U3aGJZNU9NX1FZVUQtSm1PR1JCdnktUFNKa0JNak4zTHBaQ1NwckZwWUg4ZHFnNWlac0xGVUNtRVVMNmdSWUJmbUV4b3l2ZkRWeEJ2OV9ubThfN2F2Vjd6MWhsU1VkV09GMDFSUk5jTlMyVGRmSWNmTUMxc3Z3OVpGelcwZ1pFRWlfQUM0d3FTV0xIQnMzcklOOGZldWZ4ZlFTelRSZjVMTjhRaVhaWi1zbmJOT0ppQWxrbjFGcFI?oc=5", "source_name": "Reuters", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeV9feXBaekdJMVZzOEdEQzByUG1UTW0wdFRNYnhvOUxyWXR3ZDNIWWZrbmlCVEJXYWtFS1hXZndLT1g1VFVJVHlyNmNBZ0VXVVhKYVMzd2t1NS05dVZBbGcwVHI1b3NaRk5ZOEhoMW1yeTdxdWNhR0FrWFpmUUlOcHg3UkJmMUJDSHl1bW0yWWk1cm9tZmNCb21KUGo3NENP?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences stock rises after FDA approves HDV treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNQzdockRteGt3QURfc0JLbTJldXNERmZtS1A2NXFwaC1YQnZRVzFwOUVhczVycjRyZzlaUG4tOXVTSUJ2dVdTLVFmNzVKbDA1bGY0XzBQME1ROENPV01SUEdTWDlxdnZ3aHB3LTNBYl9LOGJQZnhYalJpLUZRdk5TYUNod1ZaTmtsbmM2VUQ0bmtHUnJrX2Rscl9EbUZLSnRqZ0g0V3QtNDFsMTN5cUpIc05UQjdLN0VuX2dtMjBHMA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Just Told Investors What to Watch Before December 23. Here\u2019s What the Data Says About GILD Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMy1FZks3blJfcHlFUXMxclRvdWtELUZ1Vk80amFiMlJKUGdIamE3UjJmX3JmOXpUN2ZTRXBEWm5JdF9KejJXMW5DZ1k5MDlydTZUdkVxUlVUQ1JIN3I0WVowTlRRS1dscGtKOC1tQjNLZjd5dGNEanZweFp3UUsxc193blRFZjR2WjFMTVBvbUc1NS1Td29wZ0U2azEwR3IwZTdlMk9IdUhVWllacHFmVl9lR2RJNThRbWhEMjZIV2x2RUpieW83VE4xTE1mb0dmb0E?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMS1kN2xmaTh4MTlPODdvOE12di05bS1RbFhpNHg2dDJGSXlZYXV1T2MzNEYzZUMwQnB2YWZVNnZEdE51SjdFdE1nSDRRajh3Xzd4V2x1Smc1NTVFUG0xQlBjRU1ZbWUtUWE2VG03VUx2dXE0Unk1R2Nfc0VVRkFpZkh2LVZZQmlTM1lBem5xYWxVeFNUYnlCbkNIdEdEQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOalRrOEs3M2UtWUxwQnhjU3VwRmZLOUtfM1ZfYTBpZ0haTG41cnU4V3R6RDRxZHFhdVBMbTlxaldaWkxLWUVIbWQ1NlVvOGZjeVFxSjdEdlJHQ0hPdFFCWlhrbkQ1dHZiV1NrcmlUMmhqNnNsS2Rudnh6ZUE0Vll1SnMtLTg2VlQ2bmUzQ1BnS1QzTEVwUXBrTzJuVFVGcXVSQ1dBbHFCWTFOQ2NfYjdqVFBWbGY2bEhIZV9VcUhoN01ORFVsTU9J?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVFlVWF4b3BsZlAtbGZmaWFxVXRfQ0V4Z0F5elpteGYzWHhvWWpxV2lKejRmTkItNDF3SDlTcXdidm1qeTRNeEU1Vl9hUGdXWlp0MVpySlFoQlVXbTFQalVWdTU3Uld1SHUxZ212MGZmakVDSUZHNmREZmN0N2IyY1FLWFNzVXFQVG1JVWM2YlFQTEtpNkNYbjg5d0JiNUp2YkYyd180dktEUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead expands HIV prevention drug access to 3 million people", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOM1JRcTBLS19uTkNqb0ROZ2ROQTJjRERoZllGd0lHSTY2TTJEWmFOc0FYT3YxY0t6R3BRbVhpSE9PTEpoWklBeWFGOVRDMnZRbnpfX2d6eG13cnNQOGpTdTdUdUVZdXc2d1p6aGFXZ3Y4bDREM3hqak5LLVhhU2Y0ZW5jQkR2R3d5TjRFM1A5b3J1b0pmZXBQOU9TR0V0UmpWTy1DZzhYXzUzbERNU3g4YzNBZ1ZaNUlyb1E?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's Stock Price is Expected to Rise to $160\uff0cGilead\u2019s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNYktKSmxGRjVHQk1iUW0tcXdHX1N2UmQ3clhIR1JsQk5DUUhIbm01a0lldmUybm0xSEVUQ3dYcVRMVnA1UUJfcERUQVN1U1NPUW52aU05b215TEEyUVl1Q1Z6bFYwVGVkekw0NW5QanhoeG9XLVF3MnF4NU9OaENrLXFFSWZqdkt0czVHb245UjlLRzhnSFF4enc3TkNWejg4cWttempqclU0V203MWxCZWlZTmwzOGRBX2FrTkswTHV2X1JjZHlqQ3BCb292UQ?oc=5", "source_name": "TradingKey", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNU2lzd19MT2M4eDUxWkdoS09fb0lzZWFveDZRc3JGM2UyVUo4WXc5NEkzVDZwbEFuaUJwaXhBSU81cXlQLUJza1RhQ3FscWczaGt3RWVnQnJJMHJBUE5tblphOWNta3JycWEzbEZzYXgxRUtDZTgxLTlMbU9kaTJGaGxlbHd0RzExQl9aODdoRWVrc01WdFpUYmhob2U?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRU1kVU9JTVpDcEpETGFpZGlxUWc1UnZhY3pvMzBsU3k3UV9PaWsxaTVYd3hqODZMZHJLT2kxbUFrM3hKWEpzMUNBOUpIelJVOWdIM1ozaW9hNHJic2RSanItaFZ0cXpRejhGRG9JOU50R3RielBFb05wTjhCcW1SYzNVOWlPUTExcUszWFpjUm50ZHVjOXd2T3I2d1g?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNSzZOaUxUMTYtMlkyeUlDMlVjN3EtaDRrbmxnRDdGUVVwLXd4cFdwY1FjZ3o4TmswalZRNTREOGY1SG5HcDA2UGhQSEFxaFJNTG9Bc3dBUHQ0NFpnNjB4cjZXcjJDUWlKSTlCakdZaFQwS01FZWtnRGI2U1Qxa1E3UUhUYnFQRkxqVF9pT2dZZEJjVGJsbUhNOUF3T1ItRGhkenhmYlNfbnBMZUMwWWgyWTZn?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZGF0cVAyYmNKQWpiY2xQWVkxRDhxelU5V20xUlZLTThXNWZFdFlDZGxRVmRGbDhpYW5mRG1aRV9aRVhybUxfYnBtRHJQM2NRVUZlcGRWbFdRYm9TUksyLU04SzVoOU9MZXRkLTUwclowWnEwQ1VRdVpNb1plM21UbmVZdWNCTUdkbjg3ZGNNT3J6b3VDeG5xUFY5aW9SUldzU09xcEh1SXpfSzJhR3hMeFc1MS1wdw?oc=5", "source_name": "TradingView", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOFhxZkdLVkg0QXJ5SHZhU1ByRWZMaV9lTGxhMm9jZ3YwcFVMUG4tS24ycVljaHZqZjhJdFU4RjFaRDRjU056RVFBeWstRHliUnk5Tk1tTi11OFdXdE43aDFVcHpTVE5nNTFmNWpPQW5ucE4yT1N3aFJRSS0yNm1YTDdvT2JncDJ1?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How to Buy Gilead Sciences Stock (GILD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOaG9xc2pYNGNuR09LY1dXRUkxNmNDU1lWMG13S1BPdzVUWV9SQkxiOUF5UWhYQ3dmcDdkRHN0OW1SRlVMaERzR1h5QWduY0JZUjRmV0lwUDVJQnBjMEZZejlQOXlXemFOdjd6M0xHem5SLWg2amtQMkhJRm0wY3lHNXZNVkRUbTczb0YxNkhHYWV2NmQ1Ync?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPM2N2QXVuQV9yX1huaWlEQ096Q3pyY245Z0FLdGwxTGc2dXlJZDlpMVVIaU5RcWZZaUxiTy10RDN0cXBxMTZNemZzUldXYS1VaFd3MUlLbVR2QjNfQVNLcWNGTUtaOHJkS05LNFVUYmJHM2FWUWlfU25uYVBudmVFNHZ5bE51OVE0NDBmNVFOSGplMlZBSW1MNw?oc=5", "source_name": "TIKR.com", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZHpSRW9PU2dWLUFwMnk4ZGdvMjVMQjBRUWYyQk5kbFZxaS1MVko5WGlxZzFoeUhVdm5KeGhwQkRSbWhjV1ptQ1B1T084cFB3Q21vYWlPWTJZa1ptcGtNdmxwb0pHa0FHRTBWb1N4MUVQaEdpM01ROTBnTHEtMGFQT1E1VWpneGV0eHNEWFRucWRtaEYxRXZxT2d1YUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:11:31+00:00", "published_display": "15 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier", "summary": "Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025. ", "url": "https://www.stocktitan.net/sec-filings/GILD/144-gilead-sciences-inc-sec-filing-54444559e606.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:38:11", "published_display": "15 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 GILEAD SCIENCES For: 15 July By Investing.com", "summary": "This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-144-gilead-sciences-for-15-july-93CH-4736060", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:25:35", "published_display": "15 Jul 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBB ETF Holds Fewer Bets Than You Think", "summary": "The iShares Biotechnology ETF (IBB) appears diversified with 249 stocks, but its effective holdings are closer to 35 equally weighted positions due to significant concentration. The top ten holdings account for 44% of its assets, with Vertex Pharmaceuticals, Amgen, and Gilead Sci", "url": "https://www.trefis.com/stock/ibb/articles/607327/ibb-etf-holds-fewer-bets-than-you-think/2026-07-15", "source_name": "Trefis", "published_at": "2026-07-15T16:12:08", "published_display": "15 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?", "summary": "Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced \"death crosses\" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% divid", "url": "https://247wallst.com/investing/2026/07/15/is-the-bearishness-around-pfizer-and-gilead-sciences-a-contrarian-opportunity/", "source_name": "24/7 Wall St.", "published_at": "2026-07-15T13:10:37", "published_display": "15 Jul 2026 13:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Gilead\u2019s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences (GILD) Investors?", "summary": "Gilead Sciences reported a Q3 revenue beat of US$6.96 billion, exceeding analysts' expectations by 1.5%, but concurrently issued a softer full-year earnings-per-share outlook. This outcome suggests that while sales are strong, the company faces challenges in translating this grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/should-gileads-revenue-beat-but-softer-eps-outlook-require-a", "source_name": "Simply Wall Street", "published_at": "2026-07-15T04:10:44", "published_display": "15 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day", "summary": "Shares of Gilead Sciences Inc. (GILD) closed down 1.04% at $130.04, despite an overall positive trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average seeing gains. The company's stock is currently trading 17.32% below its 52-week high of $1", "url": "https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-despite-losses-on-the-day-5e21e01f-dd5991da1067", "source_name": "MarketWatch", "published_at": "2026-07-14T16:35:00", "published_display": "14 Jul 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo", "summary": "Researchers in the Democratic Republic of Congo have initiated a trial for Gilead Sciences' experimental antiviral, obeldesivir, to be used as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak. The study, aimed at reducing the risk of Ebola infection after conta", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/congo-begins-trial-gileads-experimental-antiviral-ebola-bundibugyo-2026-07-14/", "source_name": "Reuters", "published_at": "2026-07-14T12:48:27", "published_display": "14 Jul 2026 12:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD)", "summary": "This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Medtronic (MDT), Quest Diagnostics (DGX), and Gilead Sciences (GILD). Analysts from Bank of America Securities maintained Buy ratings for all three, setting price targets that", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/3268979/analysts-offer-insights-on-healthcare-companies-medtronic-mdt-quest-diagnostics-dgx-and-gilead-sciences-gild/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T11:27:02", "published_display": "14 Jul 2026 11:27", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1", "summary": "This article analyzes the Q1 performance of Gilead Sciences and other key players in the therapeutics industry. While the sector generally performed well, with revenues beating estimates and share prices rising, individual companies showed varied results. Gilead Sciences reported", "url": "https://www.tradingview.com/news/stockstory:d119f2733094b:0-spotting-winners-gilead-sciences-nasdaq-gild-and-therapeutics-stocks-in-q1/", "source_name": "TradingView", "published_at": "2026-07-14T03:08:30", "published_display": "14 Jul 2026 03:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer", "summary": "Gilead Sciences, Inc. has announced that it has received all necessary regulatory approvals for its acquisition of Arcellx and has extended the tender offer for all outstanding shares of Arcellx common stock. The Australian Competition and Consumer Commission (ACCC) approved the ", "url": "https://www.natlawreview.com/press-releases/gilead-receives-all-required-regulatory-approvals-acquisition-arcellx-and", "source_name": "The National Law Review", "published_at": "2026-07-14T01:44:29", "published_display": "14 Jul 2026 01:44", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) AGM 2026 Summary", "summary": "The Gilead Sciences (GILD) AGM 2026 summary details the meeting's agenda, including the re-election of all nine director nominees. The board opposed shareholder proposals concerning an independent board chair, a report on patent exclusivity impact on patient access, and a report ", "url": "https://quartr.com/events/gilead-sciences-gild-agm-2026_3YENDubu", "source_name": "Quartr", "published_at": "2026-07-13T17:07:52", "published_display": "13 Jul 2026 17:07", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock outperforms competitors on strong trading day", "summary": "Gilead Sciences Inc. (GILD) saw its stock advance 1.21% to $131.40 on Monday, outperforming the broader market which experienced declines. The S&P 500 Index fell 0.79%, and the Dow Jones Industrial Average dropped 0.26% on the same trading day. This rise for Gilead Sciences Inc. ", "url": "https://www.marketwatch.com/data-news/gilead-sciences-inc-stock-outperforms-competitors-on-strong-trading-day-c04575bc-b4ac0b949a9e?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-13T16:35:00", "published_display": "13 Jul 2026 16:35", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD) Stock Analysis: Promising 21.93% Upside Amid Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLUE4TjFuWVFnYXp6R2NkZlhUblVRRkw5NTRpTGt0ZGhzZnBXQ09ZREFvTndDYTBEeDJveC1zMGk0R09Zb3EyNllpVm9vRmdtM2k2T3ByMy1uNFpTWENNT0p2TmxRcnlmd0E3bEFPbTM1eGN2Z1czNnY3UG0tdTF0ZUdhNXYxMnFkc0NwRVNyMlZENkNac0lvMHgtaGx1YkRjc2dEbmcxN21KNFZ3cHpHTGViOGVjMDIya1lmWkdPa29HaFI5VE5JazVQUi1GUTdESmJF?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:07+00:00", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.", "summary": "", "url": "https://finance.yahoo.com/m/c62745d4-bc96-3cd9-977e-fb163ba9e19e/many-investors-are-still.html", "source_name": "Motley Fool", "published_at": "2026-07-12T13:43:00+00:00", "published_display": "12 Jul 2026 13:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Gilead Sciences, Inc. Stocks", "summary": "This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold shares of Gilead Sciences, Inc. (1GILD). The list details each ETF's market value, weight of Gilead stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, an", "url": "https://www.tradingview.com/symbols/MIL-1GILD/etfs/", "source_name": "TradingView", "published_at": "2026-07-11T10:37:49", "published_display": "11 Jul 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)", "summary": "Wells Fargo analyst Mohit Bansal has reiterated a Buy rating for Gilead Sciences (GILD) with a $165.00 price target. This comes after Gilead reported quarterly revenue of $6.96 billion and a net profit of $2.02 billion, exceeding the previous year's figures. JPMorgan also issued ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3236888/wells-fargo-sticks-to-their-buy-rating-for-gilead-sciences-gild/", "source_name": "The Globe and Mail", "published_at": "2026-07-11T10:25:49", "published_display": "11 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 -- Data Talk", "summary": "Gilead Sciences is experiencing a significant stock decrease, down over 4% today. This puts the company on track for its largest single-day percentage decrease since July 2025, indicating a notable market reaction to recent events or news concerning the biopharmaceutical firm.", "url": "https://www.moomoo.com/news/post/72793765/gilead-sciences-down-over-4-on-pace-for-largest-percent", "source_name": "Moomoo", "published_at": "2026-07-11T06:07:58", "published_display": "11 Jul 2026 06:07", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts", "summary": "Gilead Sciences (GILD) stock declined 3.72% in its latest trading session while the broader market saw gains. Despite this daily dip, GILD's stock has outperformed both the Medical sector and the S&P 500 over the past month. Investors are awaiting Gilead's upcoming earnings repor", "url": "https://sg.finance.yahoo.com/news/gilead-sciences-gild-stock-dips-220003798.html", "source_name": "Market source", "published_at": "2026-07-10T21:37:41", "published_display": "10 Jul 2026 21:37", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look at Gilead Sciences Inc (GILD) After 3.7% Decline -- GF Value $96.09 vs Price $129.83", "summary": "Gilead Sciences Inc (GILD) shares dropped 3.7% today, with its current price of $129.83 significantly exceeding its GF Value\u2122 of $96.09, indicating it is 35.1% overvalued. The stock's GF Score\u2122 of 69/100 suggests above-average performance, but recent insider selling of $10.8 mill", "url": "https://www.gurufocus.com/news/8954073/a-look-at-gilead-sciences-inc-gild-after-37-decline-gf-value-9609-vs-price-12983", "source_name": "GuruFocus", "published_at": "2026-07-10T21:22:40", "published_display": "10 Jul 2026 21:22", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors", "summary": "The article states that Gilead Sciences Inc. (GILD) stock underperformed on Friday compared to its competitors. No specific financial data for Gilead or its peers is provided in the very brief article.", "url": "https://www.msn.com/en-us/money/topstocks/gilead-sciences-inc-stock-underperforms-friday-when-compared-to-competitors/ar-AA27FnOL?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-10T20:42:44", "published_display": "10 Jul 2026 20:42", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lakefront draws Equal Weight rating at Morgan Stanley (LKFT)", "summary": "Morgan Stanley has resumed coverage of Lakefront Biotherapeutics (LKFT) with an \"Equal Weight\" rating and a $30 price target. This re-initiates coverage after Lakefront's acquisition of Ouro Medicines in June. The $1.7 billion deal was partly funded by Gilead.", "url": "https://seekingalpha.com/news/4612970-lakefront-draws-equal-weight-rating-morgan-stanley", "source_name": "Seeking Alpha", "published_at": "2026-07-10T17:08:13", "published_display": "10 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement", "summary": "Gilead Sciences Inc (GILD) stock fell by 3.26% on July 10, primarily due to the failure of a Phase 3 solid tumor clinical trial and broader macroeconomic pressures. Strong employment data contributed to increased Treasury yields, negatively impacting biotech valuations. Analysts ", "url": "https://www.tradingkey.com/news/market-movers/262023373-market-movers-gild-20260710", "source_name": "TradingKey", "published_at": "2026-07-10T16:14:48", "published_display": "10 Jul 2026 16:14", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T15:28:27+00:00", "published_display": "09 Jul 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-sciences-gild-cheap-trodelvy-151037212.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T15:10:37+00:00", "published_display": "09 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-wins-trodelvy-071211614.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T07:12:11+00:00", "published_display": "09 Jul 2026 07:12", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-sciences-gild-russell-growth-061146402.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T06:11:46+00:00", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Keeps Buy Rating on Gilead (GILD)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/morgan-stanley-keeps-buy-rating-204826865.html", "source_name": "Insider Monkey", "published_at": "2026-07-08T20:48:26+00:00", "published_display": "08 Jul 2026 20:48", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Could Be 53% Below Fair Value After Trodelvy Approval", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T12:13:04+00:00", "published_display": "08 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Trodelvy\u2019s First-Line TNBC Approval Redefine Gilead Sciences\u2019 (GILD) Oncology-Led Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQb1Y3U09pU3plcjhBLVR4YnlEWmpXY3dFRHI4NXlnck5mMjN2WTQ3X2IxYVlULUVSVGM2T1lFY2xIb0VqaE9rZ1NkWTBKS3FMTFpReDM5MlBZcEZfQ3lrNUxGNl9nRnBDV2cybE5LTUFJNUdIdklTRVRvbWNobkpkbU1ibDFXVkhGdjEtU2ZhdGJoUFBibldISDBB?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Could This FDA Milestone Unlock Gilead\u2019s (GILD) Next Big Growth Driver?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQT29NS01sMmtTVjF4MDhFYXpGUU9yMTFVSjFIMXRkRGYxMEZXR294X2ZfU2lNbEhPQ1Qyd1hxM0JjUm00UDFfOVJEQk8xVWp3QldqRXVLb0RIZVFPdjNFUnhwS2hwbGhfVGliS0JoQzM0b3c5ZjFwQXRXNkcyS1VxRVpYMktLX2plTGdzbWtkVTUxemtfZHlCcTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPQk1DTTdDeWFIb0JSZWdIamtYVzlxcnJ5THpBM2lfR0VLQ1lqamRMVS16eThoOUcyZjA3UmpNTkVlVzdsYVJtV04tUy05S1NVQkZ5Q2hMa1NzUDQxUThNcU5Qc1hGSTV3NUs4eEg5azhEX0xyaWJGQm93UmFnejg2bk5UdUM3bGs2bWV6YTZ4WkJRX1RlTFR5QUI1TWNBZFpUZlMxekZYMHY4UmV2YlNHSHM1aTBpdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNajlJV3A3cnJBMngzSGVaWlRZUmFzRWZhMmdBZlYxd3RFMUlfdTlEenNMbHVPMmVMWlg5MVd4Vlk2MFFjbGRkTC11Y0ZYVWlVV3ZYLXFMZ21nRmt0cnVfNDFkbEpqVzJoLUI2aWpIMkdRUkRheGR1V1FMV2N5Qk5XSF9xZExjUzFxd3RuX3NDWGt1Tk1fdkRzMU5wRnlNdVhqVWtRamE3QWEtY0JpUEpjU2ZSbFJTSkdJd1ZoRUF1VkI2ZmIxUzB2dHhXRjFNTnAwcFBYQl9IRG9yeHdtZEVsSQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ3RhTlFnWC1qTkw3YXFtQ0pBSmEtYW8zRGdPUzhJNVhQQjhBUmtlRkszQzJNaGM3MXlYb0tmV0tWWHNscG8yV1pIaXV0NnJLRVhpaF9Ub3NWYWxLOUdhQ2JrSnlkSnBHenloWGsxRUtDaHhReHNkZWVEVTA5di01ZmI3QVRVX09SREwzQkJfSUJVNGNEM1lrUVRsR3hrdw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQR3hpb21Xd2lQalJiYnBZWlQ1QmhabDZrUlhQRjRfMnlfeUFnTEE3ZW9QZ3IyYkdtUGhiZTREOGc1RFI2UjRjeU1DcnZnTWhtR3JrOWhKNXlqQm9oWG8yZjltZ3hNdDFqTFJXWGRrYmp4bTZjSjlTV3g3Sk1yVk1vQ0ZsSkQyZlRXcEpjeUtzSXNyQXdUQXlGeFd1bS1oWUxqcjBmS2JxRXBIcDJw?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's drug wins first-ever US approval for deadly liver infection", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOY1U3aGJZNU9NX1FZVUQtSm1PR1JCdnktUFNKa0JNak4zTHBaQ1NwckZwWUg4ZHFnNWlac0xGVUNtRVVMNmdSWUJmbUV4b3l2ZkRWeEJ2OV9ubThfN2F2Vjd6MWhsU1VkV09GMDFSUk5jTlMyVGRmSWNmTUMxc3Z3OVpGelcwZ1pFRWlfQUM0d3FTV0xIQnMzcklOOGZldWZ4ZlFTelRSZjVMTjhRaVhaWi1zbmJOT0ppQWxrbjFGcFI?oc=5", "source_name": "Reuters", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNeV9feXBaekdJMVZzOEdEQzByUG1UTW0wdFRNYnhvOUxyWXR3ZDNIWWZrbmlCVEJXYWtFS1hXZndLT1g1VFVJVHlyNmNBZ0VXVVhKYVMzd2t1NS05dVZBbGcwVHI1b3NaRk5ZOEhoMW1yeTdxdWNhR0FrWFpmUUlOcHg3UkJmMUJDSHl1bW0yWWk1cm9tZmNCb21KUGo3NENP?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences stock rises after FDA approves HDV treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNQzdockRteGt3QURfc0JLbTJldXNERmZtS1A2NXFwaC1YQnZRVzFwOUVhczVycjRyZzlaUG4tOXVTSUJ2dVdTLVFmNzVKbDA1bGY0XzBQME1ROENPV01SUEdTWDlxdnZ3aHB3LTNBYl9LOGJQZnhYalJpLUZRdk5TYUNod1ZaTmtsbmM2VUQ0bmtHUnJrX2Rscl9EbUZLSnRqZ0g0V3QtNDFsMTN5cUpIc05UQjdLN0VuX2dtMjBHMA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Just Told Investors What to Watch Before December 23. Here\u2019s What the Data Says About GILD Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMy1FZks3blJfcHlFUXMxclRvdWtELUZ1Vk80amFiMlJKUGdIamE3UjJmX3JmOXpUN2ZTRXBEWm5JdF9KejJXMW5DZ1k5MDlydTZUdkVxUlVUQ1JIN3I0WVowTlRRS1dscGtKOC1tQjNLZjd5dGNEanZweFp3UUsxc193blRFZjR2WjFMTVBvbUc1NS1Td29wZ0U2azEwR3IwZTdlMk9IdUhVWllacHFmVl9lR2RJNThRbWhEMjZIV2x2RUpieW83VE4xTE1mb0dmb0E?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMS1kN2xmaTh4MTlPODdvOE12di05bS1RbFhpNHg2dDJGSXlZYXV1T2MzNEYzZUMwQnB2YWZVNnZEdE51SjdFdE1nSDRRajh3Xzd4V2x1Smc1NTVFUG0xQlBjRU1ZbWUtUWE2VG03VUx2dXE0Unk1R2Nfc0VVRkFpZkh2LVZZQmlTM1lBem5xYWxVeFNUYnlCbkNIdEdEQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOalRrOEs3M2UtWUxwQnhjU3VwRmZLOUtfM1ZfYTBpZ0haTG41cnU4V3R6RDRxZHFhdVBMbTlxaldaWkxLWUVIbWQ1NlVvOGZjeVFxSjdEdlJHQ0hPdFFCWlhrbkQ1dHZiV1NrcmlUMmhqNnNsS2Rudnh6ZUE0Vll1SnMtLTg2VlQ2bmUzQ1BnS1QzTEVwUXBrTzJuVFVGcXVSQ1dBbHFCWTFOQ2NfYjdqVFBWbGY2bEhIZV9VcUhoN01ORFVsTU9J?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSVFlVWF4b3BsZlAtbGZmaWFxVXRfQ0V4Z0F5elpteGYzWHhvWWpxV2lKejRmTkItNDF3SDlTcXdidm1qeTRNeEU1Vl9hUGdXWlp0MVpySlFoQlVXbTFQalVWdTU3Uld1SHUxZ212MGZmakVDSUZHNmREZmN0N2IyY1FLWFNzVXFQVG1JVWM2YlFQTEtpNkNYbjg5d0JiNUp2YkYyd180dktEUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead expands HIV prevention drug access to 3 million people", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOM1JRcTBLS19uTkNqb0ROZ2ROQTJjRERoZllGd0lHSTY2TTJEWmFOc0FYT3YxY0t6R3BRbVhpSE9PTEpoWklBeWFGOVRDMnZRbnpfX2d6eG13cnNQOGpTdTdUdUVZdXc2d1p6aGFXZ3Y4bDREM3hqak5LLVhhU2Y0ZW5jQkR2R3d5TjRFM1A5b3J1b0pmZXBQOU9TR0V0UmpWTy1DZzhYXzUzbERNU3g4YzNBZ1ZaNUlyb1E?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead's Stock Price is Expected to Rise to $160\uff0cGilead\u2019s $5 Billion Tubulis Deal Could Reshape the Cancer Drug Market of America", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNYktKSmxGRjVHQk1iUW0tcXdHX1N2UmQ3clhIR1JsQk5DUUhIbm01a0lldmUybm0xSEVUQ3dYcVRMVnA1UUJfcERUQVN1U1NPUW52aU05b215TEEyUVl1Q1Z6bFYwVGVkekw0NW5QanhoeG9XLVF3MnF4NU9OaENrLXFFSWZqdkt0czVHb245UjlLRzhnSFF4enc3TkNWejg4cWttempqclU0V203MWxCZWlZTmwzOGRBX2FrTkswTHV2X1JjZHlqQ3BCb292UQ?oc=5", "source_name": "TradingKey", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNU2lzd19MT2M4eDUxWkdoS09fb0lzZWFveDZRc3JGM2UyVUo4WXc5NEkzVDZwbEFuaUJwaXhBSU81cXlQLUJza1RhQ3FscWczaGt3RWVnQnJJMHJBUE5tblphOWNta3JycWEzbEZzYXgxRUtDZTgxLTlMbU9kaTJGaGxlbHd0RzExQl9aODdoRWVrc01WdFpUYmhob2U?oc=5", "source_name": "TIKR.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRU1kVU9JTVpDcEpETGFpZGlxUWc1UnZhY3pvMzBsU3k3UV9PaWsxaTVYd3hqODZMZHJLT2kxbUFrM3hKWEpzMUNBOUpIelJVOWdIM1ozaW9hNHJic2RSanItaFZ0cXpRejhGRG9JOU50R3RielBFb05wTjhCcW1SYzNVOWlPUTExcUszWFpjUm50ZHVjOXd2T3I2d1g?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNSzZOaUxUMTYtMlkyeUlDMlVjN3EtaDRrbmxnRDdGUVVwLXd4cFdwY1FjZ3o4TmswalZRNTREOGY1SG5HcDA2UGhQSEFxaFJNTG9Bc3dBUHQ0NFpnNjB4cjZXcjJDUWlKSTlCakdZaFQwS01FZWtnRGI2U1Qxa1E3UUhUYnFQRkxqVF9pT2dZZEJjVGJsbUhNOUF3T1ItRGhkenhmYlNfbnBMZUMwWWgyWTZn?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZGF0cVAyYmNKQWpiY2xQWVkxRDhxelU5V20xUlZLTThXNWZFdFlDZGxRVmRGbDhpYW5mRG1aRV9aRVhybUxfYnBtRHJQM2NRVUZlcGRWbFdRYm9TUksyLU04SzVoOU9MZXRkLTUwclowWnEwQ1VRdVpNb1plM21UbmVZdWNCTUdkbjg3ZGNNT3J6b3VDeG5xUFY5aW9SUldzU09xcEh1SXpfSzJhR3hMeFc1MS1wdw?oc=5", "source_name": "TradingView", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOFhxZkdLVkg0QXJ5SHZhU1ByRWZMaV9lTGxhMm9jZ3YwcFVMUG4tS24ycVljaHZqZjhJdFU4RjFaRDRjU056RVFBeWstRHliUnk5Tk1tTi11OFdXdE43aDFVcHpTVE5nNTFmNWpPQW5ucE4yT1N3aFJRSS0yNm1YTDdvT2JncDJ1?oc=5", "source_name": "Market source", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How to Buy Gilead Sciences Stock (GILD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOaG9xc2pYNGNuR09LY1dXRUkxNmNDU1lWMG13S1BPdzVUWV9SQkxiOUF5UWhYQ3dmcDdkRHN0OW1SRlVMaERzR1h5QWduY0JZUjRmV0lwUDVJQnBjMEZZejlQOXlXemFOdjd6M0xHem5SLWg2amtQMkhJRm0wY3lHNXZNVkRUbTczb0YxNkhHYWV2NmQ1Ync?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPM2N2QXVuQV9yX1huaWlEQ096Q3pyY245Z0FLdGwxTGc2dXlJZDlpMVVIaU5RcWZZaUxiTy10RDN0cXBxMTZNemZzUldXYS1VaFd3MUlLbVR2QjNfQVNLcWNGTUtaOHJkS05LNFVUYmJHM2FWUWlfU25uYVBudmVFNHZ5bE51OVE0NDBmNVFOSGplMlZBSW1MNw?oc=5", "source_name": "TIKR.com", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 110, "total_relevant": 52, "sentiment_summary": {"positive": 17, "negative": 9, "neutral": 26, "score": 54, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 22.85, "count": 39}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.0, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}], "positive_events": 17, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 129.83, "latest_week": "2026-07-10", "one_week_move": -1.1, "four_week_move": 4.1, "twelve_week_move": -5.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.681712, "market_dynamics_buy_signal": false, "relative_strength": -11.551333, "fair_value_gap": 36.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.7535, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.1% over one week, +4.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 4}, {"label": "TIKR.com", "count": 4}, {"label": "The Globe and Mail", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Simply Wall St.", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "MarketWatch", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 39}, {"label": "Earnings", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.1% over one week, +4.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "GILD (NASDAQ: GILD) holder plans 3,000-share common stock sale"}], "updated_at": "2026-07-16T04:34:23.107133+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}